SCHEMBL6882137

SCHEMBL6882137

CCCCOC(=O)C(OC(=O)SCC)OC(=O)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
ATM Q13315 1/20 0.34
PRKCA P17252 1/20 0.33
TSHR P16473 3/20 0.33
HPGD P15428 1/20 0.33
LMNA P02545 2/20 0.31
ESR1 P03372 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
PDE4D Q08499 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
NAAA Q02083 1/20 0.30
HSD17B10 Q99714 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887053 0.85 PRKCA (0.37) PRKCA
SCHEMBL6885532 0.83 ALDH1A1 (0.32) ALDH1A1ATMSMN1; SMN2
SCHEMBL7878977 0.81 PRKCA (0.36) PRKCALMNA
SCHEMBL6882617 0.81 ALDH1A1 (0.39) ALDH1A1ATMPRKCATSHRHPGD
SCHEMBL6885815 0.74 ALDH1A1 (0.41) ALDH1A1ATMTSHRHPGDLMNA
SCHEMBL6887712 0.74 ALDH1A1 (0.41) ALDH1A1ATMTSHRHPGDLMNA
SCHEMBL1507276 0.72 PRKCA (0.37) ALDH1A1PRKCA
SCHEMBL126843 0.70 ALDH1A1 (0.56) ALDH1A1ATMTSHRHPGDLMNA
SCHEMBL638234 0.69 PRKCA (0.35) PRKCA
Hydrochloric Acid SCHEMBL29154738 0.69 ALDH1A1 (0.54) ALDH1A1ATMTSHRHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040254182-A1 Enhanced propertied pharmaceuticals ROHM AND HAAS COMPANY 2004-12-16 US disclosed
EP-1272463-A1 ENHANCED PROPERTIED PHARMACEUTICALS ROHM AND HAAS COMPANY (US) 2003-01-08 EP disclosed
WO-2002072559-A1 PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS ROHM AND HAAS COMPANY (US) 2002-09-19 WO disclosed
US-20010039343-A1 Process to intermediates for biologically active compounds MULVIHILL MARK JOSEPH (US) 2001-11-08 US disclosed
WO-2001056358-A2 ENHANCED PROPERTIED PESTICIDES ROHM AND HAAS COMPANY (US) 2001-08-09 WO disclosed
WO-2001054481-A2 ENHANCED PROPERTIED PHARMACEUTICALS ROHM AND HAAS COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254182-A1 Enhanced propertied pharmaceuticals ABCB1, ABCB11, ABCG2 ALDH1A1 118/4885ATM 4870/4885PRKCA 4855/4885
US-20010039343-A1 Process to intermediates for biologically active compounds DDT, CYP4X1, CYP1B1 ALDH1A1 164/4885ATM 4228/4885PRKCA 1954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.